Vir Biotechnology stock: USD 150 million offering priced
Published on 11/20/2026 at 00:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOffering expands Vir's funding
- Vir priced 15 million common shares at USD 10 each on November 12.
- Underwriters received a 30-day option for up to 2.25 million additional shares.
- The clinical-stage pipeline spans chronic hepatitis delta and oncology programs.
Vir Biotechnology priced a public offering of 15 million common shares on November 12, 2026, giving the clinical-stage biopharmaceutical company a planned capital raise as it advances programs in infectious diseases and cancer. The company said the gross proceeds were expected to reach USD 150 million before underwriting discounts, commissions and offering expenses. Business Wire reported that the offering was expected to close on November 16, subject to customary closing conditions.
Terms of the capital raise
The shares were priced at USD 10 each. Vir also granted the underwriters a 30-day option to purchase up to 2.25 million additional shares at the public offering price, less underwriting discounts and commissions.
Leerink Partners, Morgan Stanley and Evercore ISI acted as bookrunning managers, while Raymond James served as co-manager. The registration statement became automatically effective upon filing with the U.S. Securities and Exchange Commission on November 12.
Pipeline remains clinical-stage
Vir Biotechnology develops medicines by using immune-system approaches against serious infectious diseases and cancer. Its disclosed clinical-stage portfolio includes treatments for chronic hepatitis delta and PRO-XTEN dual-masked T-cell engagers for solid tumors, alongside preclinical oncology programs.
The company is headquartered in San Francisco, California, and remains focused on research and clinical development rather than marketed products. Its profile therefore differs from larger commercial drugmakers, with investment outcomes tied closely to clinical progress, regulatory decisions and future partnerships.
Vir Biotechnology at a glance
- Company: Vir Biotechnology, Inc.
- ISIN: US92764N1028
- Ticker: VIR
- Exchange: Nasdaq Global Select Market
- Headquarters: San Francisco, California
Vir Biotechnology operates in the U.S. biotechnology market, where investors are also watching the broader S&P 500 environment through current market coverage.
More news and analyses on Vir Biotechnology stock are available in the company topic section.
